Amylyx Pharmaceuticals, Inc. (AMLX) – What Are Brokerages Thinking About This Stock?

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $40.71.

Several equities analysts have recently weighed in on the company. Wolfe Research upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 17th. Robert W. Baird lifted their target price on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an “outperform” rating in a report on Wednesday, August 19th. Mizuho upped their target price on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. HC Wainwright raised their price target on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Finally, Citigroup increased their target price on Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, October 15th.

Amylyx Pharmaceuticals Trading Down 2.8%

Shares of NASDAQ:AMLX opened at $28.04 on Tuesday. The stock has a market cap of $3.12 billion, a PE ratio of -19.61 and a beta of -0.10. The stock’s fifty day simple moving average is $30.68 and its two-hundred day simple moving average is $20.13. Amylyx Pharmaceuticals has a 1-year low of $10.83 and a 1-year high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). On average, sell-side analysts forecast that Amylyx Pharmaceuticals will post -1.48 earnings per share for the current fiscal year.

Insider Activity at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 9,536 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $32.46, for a total transaction of $309,538.56. Following the completion of the transaction, the insider directly owned 190,838 shares in the company, valued at approximately $6,194,601.48. This represents a 4.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James Frates sold 10,810 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $32.36, for a total transaction of $349,811.60. Following the sale, the chief financial officer directly owned 233,625 shares in the company, valued at approximately $7,560,105. The trade was a 4.42% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 60,374 shares of company stock valued at $1,815,257 in the last quarter. 10.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Large investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC purchased a new position in Amylyx Pharmaceuticals during the 3rd quarter valued at $590,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Amylyx Pharmaceuticals in the third quarter worth about $187,000. Profund Advisors LLC increased its stake in Amylyx Pharmaceuticals by 138.7% in the 3rd quarter. Profund Advisors LLC now owns 49,435 shares of the company’s stock worth $1,439,000 after buying an additional 28,725 shares during the period. ProShare Advisors LLC increased its stake in Amylyx Pharmaceuticals by 10.7% in the 3rd quarter. ProShare Advisors LLC now owns 17,360 shares of the company’s stock worth $505,000 after buying an additional 1,675 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Amylyx Pharmaceuticals by 29.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,901 shares of the company’s stock valued at $671,000 after buying an additional 5,206 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile